Replies to post #522616 on NorthWest Biotherapeutics Inc (NWBO)

[extrooper]

Your attached cartoon is so true.

[HyGro]

The non-IDH mutant GBM was less than 5% of the DCVax-L trial sample. GBM patients would prefer a approved treatment and NWBO is certainly not, and is unlikely to even be potentially approved prior to 2024.